To determine the value of PET/MRI for diagnosis, therapy monitoring, and prognostic value in patients with spondyloarthritis before and after initiation of various drug therapies.

Recruiting

• Conditions: M45.01 Axial spondyloarthrititis; M45.01

• Registration Number: DRKS00025279
• Lead Sponsor: Rheumazentrum Ruhrgebiet

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Diagnosis of spondyloarthritis (radiographic or nonradiographic axial spondyloarthritis, or psoriatic arthritis with axial skeletal involvement).
Clinical indication for [18F]fluoride PET examination.
Clinical indication for initiation of drug therapy (TNF blocker, interleuking-17 blocker, Janus kinase inhibitor, NSAID.) for a period of at least one month.

Exclusion Criteria

-Pregnancy
-Severe renal insufficiency
-Cardiac pacemaker
-Non-MR compatible foreign material
-Severe claustrophobia
-Known allergy to contrast media
-Inability to understand the patient information sheet

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate the anti-inflammatory and anti-osteoblastic effects of various drug therapies (TNF blocker, interleukin-17 blocker Janus kinase inhibitor, NSAID) in patients with active spondyloarthritis during the course.<br>To investigate the correlation of clinical disease activity with the extent and course of inflammatory changes (MRI) or increased metabolic ([18F]fluoride PET) activity.

Secondary Outcome Measures

Name	Time	Method
Comparison of the examination results of native MRI examinations in the regions of the ankle, spine and sacroiliac joints of spondyloarthritis patients before and after drug therapy, among others, with the examination results obtained by means of [18F]fluoride PET/MRI. In detail, the skeletal sites showing inflammatory activity in MRI are compared to the exact anatomical regions showing metabolic activity in [18F]fluoride PET/MRI.